#1 Clinical Trials Search in Europe

Deutivacaftor

This article explores clinical trials investigating the use of deutivacaftor, a novel drug, in combination therapy for treating cystic fibrosis. The studies aim to evaluate the long-term safety, efficacy, and tolerability of deutivacaftor when used alongside other medications in patients with cystic fibrosis across various age groups, from young children to adults.

Table of Contents

What is Deutivacaftor?

Deutivacaftor (also known as VX-561) is a new medication being developed to treat cystic fibrosis (CF). It belongs to a class of drugs called CFTR modulators, which work to improve the function of the faulty protein that causes CF.[1] Deutivacaftor is being studied as part of a triple combination therapy along with two other medications – vanzacaftor (VX-121) and tezacaftor.

How Does it Work?

In people with cystic fibrosis, a defective gene causes problems with a protein called the cystic fibrosis transmembrane conductance regulator (CFTR). This leads to thick, sticky mucus building up in various organs, especially the lungs. Deutivacaftor is designed to help the CFTR protein function more normally. Specifically, it is a “potentiator” that helps keep the CFTR protein channels open at the cell surface, allowing chloride ions to flow through properly.[2] By improving CFTR function, the goal is to reduce mucus buildup and improve symptoms of CF.

Who Can Benefit from Deutivacaftor?

Deutivacaftor is being studied in people with cystic fibrosis who have at least one copy of certain mutations in the CFTR gene, including the common F508del mutation. Current clinical trials are evaluating its use in CF patients as young as 1 year old up through adulthood.[1] The triple combination therapy containing deutivacaftor may potentially benefit up to 90% of people with CF.

Clinical Trials and Research

Several clinical trials are currently underway to evaluate the safety and effectiveness of deutivacaftor as part of a triple combination therapy:

  • A Phase 3 study is looking at long-term safety and efficacy in CF patients aged 1 year and older for up to 96 weeks.[1]
  • Another Phase 3 trial is studying the therapy in children with CF aged 1-11 years old.[2]
  • An open-label study is evaluating long-term safety and efficacy in CF patients who completed previous trials of the therapy.[3]

These studies are measuring outcomes such as:

  • Lung function – assessed by measuring forced expiratory volume in 1 second (FEV1)
  • Sweat chloride levels – an indicator of CFTR protein function
  • Quality of life scores
  • Number of pulmonary exacerbations (sudden worsening of lung symptoms)
  • Changes in weight, height, and BMI – especially important for children with CF

Safety and Side Effects

A key goal of the ongoing clinical trials is to evaluate the long-term safety and tolerability of deutivacaftor combination therapy. Researchers are closely monitoring for any adverse events, changes in lab values, ECG results, vital signs, and other safety measures.[1][2][3]

While full safety data is still being collected, CFTR modulators as a class are generally well-tolerated. Common side effects of similar drugs include headache, upper respiratory tract infections, stomach pain, diarrhea, rash, and increases in liver enzymes. However, the specific side effect profile of deutivacaftor combination therapy will become clearer as more data is gathered from clinical trials.

Future Outlook

Deutivacaftor and its companion drugs show promise as a potentially groundbreaking therapy for cystic fibrosis. If proven safe and effective in clinical trials, this triple combination could offer a new treatment option for the majority of people living with CF. Researchers hope it may significantly improve lung function, reduce exacerbations, and enhance quality of life for patients.

However, it’s important to note that deutivacaftor is still an investigational drug. More research is needed to fully understand its long-term effects and determine if it will be approved for widespread use. Patients with CF should continue to work closely with their care teams to determine the best current treatment approach for their individual situation.

Aspect Details
Drug Combination Deutivacaftor, Tezacaftor, Vanzacaftor
Age Groups Studied 1 year and older, including specific studies for ages 1-11
Primary Objectives Long-term safety, tolerability, and efficacy
Key Measurements Lung function (FEV1), sweat chloride levels, pulmonary exacerbations, quality of life
Study Duration Up to 96 weeks in some trials
Trial Phases Phase 3 studies
Special Considerations Includes pediatric formulations and assessments

FAQ

  • What is deutivacaftor and how does it work in cystic fibrosis treatment? Deutivacaftor is a medication used in combination therapy for cystic fibrosis. It works as a CFTR modulator, helping to improve the function of the defective protein that causes cystic fibrosis. When used with other drugs like vanzacaftor and tezacaftor, it aims to enhance lung function and reduce symptoms in people with certain genetic mutations causing cystic fibrosis.
  • What age groups are being studied in these clinical trials? The clinical trials are studying a wide range of age groups, from very young children to adults. One study focuses on patients aged 1 year and older, while another specifically looks at children aged 1 through 11 years. This comprehensive approach helps to understand the drug's effects across different age groups.
  • What are the main goals of these clinical trials? The main goals of these trials are to evaluate the long-term safety, tolerability, and efficacy of deutivacaftor when used in combination with other drugs for treating cystic fibrosis. Researchers are looking at various factors including adverse events, changes in lung function, sweat chloride levels, and quality of life measures.
  • How long do these clinical trials last? The duration of these trials varies, but they are designed to assess long-term effects. Some studies last up to 96 weeks (about 2 years), while others may have different timeframes. This extended period allows researchers to observe the drug's effects over time and monitor for any long-term safety concerns.
  • What are some of the key measurements being taken in these trials? Key measurements in these trials include changes in lung function (measured by FEV1), sweat chloride levels, body mass index (BMI), weight, height, and quality of life scores. The trials also monitor for adverse events, changes in laboratory values, and the number of pulmonary exacerbations experienced by participants.

Ongoing Clinical Trials on Deutivacaftor

  • Study of VX-121, Tezacaftor, and Deutivacaftor for Children Aged 1-11 with Cystic Fibrosis

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Denmark France Germany The Netherlands Sweden

  • Study on Long-Term Safety and Effectiveness of Vanzacaftor, Tezacaftor, and Deutivacaftor for Cystic Fibrosis in Patients Aged 1 Year and Older

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands Sweden

  • Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +10

Glossary

  • Cystic Fibrosis (CF): A genetic disorder that affects the lungs, pancreas, and other organs, causing thick, sticky mucus to build up and lead to infections and breathing problems.
  • Deutivacaftor: A medication used in combination therapy for cystic fibrosis, designed to improve the function of the defective CFTR protein.
  • CFTR: Cystic Fibrosis Transmembrane Conductance Regulator, the protein that is defective in people with cystic fibrosis.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function that indicates how much air a person can exhale in one second.
  • Sweat Chloride (SwCl): A measure of the amount of salt in sweat, used as a diagnostic test for cystic fibrosis and to monitor treatment effectiveness.
  • Pulmonary Exacerbation (PEx): A worsening of lung symptoms in cystic fibrosis patients, often requiring additional treatment or hospitalization.
  • BMI: Body Mass Index, a measure of body fat based on height and weight, used to assess nutritional status in CF patients.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Triple Combination Therapy: A treatment approach using three medications together, in this case, deutivacaftor, tezacaftor, and vanzacaftor.
  • Open-label Study: A type of clinical trial where both the researchers and participants know which treatment is being administered.

References

  1. http://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-vanzacaftor-tezacaftor-and-deutivacaftor-for-cystic-fibrosis-in-patients-aged-1-year-and-older/
  2. http://clinicaltrials.eu/trial/study-of-vx-121-tezacaftor-and-deutivacaftor-for-children-aged-1-11-with-cystic-fibrosis/
  3. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-vx-121-tezacaftor-and-deutivacaftor-in-patients-with-cystic-fibrosis/